



STIC Search Report

Biotech-Chem Library

Database Tracking Number: 118416

Ybille Delacroix
on: rem 4c85 &4c70
nit: 1614
day, April 01, 2004

Serial Number: 09/676032

From: Mary Hale
Location: Biotech/Chem Library
Rem 1D86
Phone: 2-2507

Mary.Hale@uspto.gov

Search Notes

hed-

and usage

Feel free to contact me if you
have any questions.

SEARCH REQUEST FORM

Requestor's Name: C. DELACROIX Serial Number: 09 1676,032
Date: 3-31-04 Phone: 272-0572 Art Unit: 1614

Search Topic:

Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevant citations, authors, keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevant claim(s).

Rm: 4C85 *Box 4C70*
Please search the attached
compounds & compositions Ther B.
Thanks
CM

Rush Search
Approved

TK Page

SPE, AUG 16 15

920
9.10

please
rush!

Thanks
CM

of Agyon
5. Quada
J. Camden

STAFF USE ONLY


Date completed: 4/11
Searcher: Ulang
Terminal time: _____
Elapsed time: _____
CPU time: _____
Total time: 10
Number of Searches: _____
Number of Databases: _____

Search Site
____ STIC
____ CM-1
____ Pre-S
Type of Search
____ N.A. Sequence
____ A.A. Sequence
____ Structure
____ Bibliographic

Vendors
____ IG
27232 STN
____ Dialog
____ APS
____ Geninfo
____ SDC
____ DARC/Questel
____ Other

O. Delacroix
676 032

d 13 que stat;fil medl,hcapl,biosis,embase;s 13 and (cancer? or carcino? or
mour or tumor or melanoma)
STR



ODE ATTRIBUTES:
FAULT MLEVEL IS ATOM
FAULT ECLEVEL IS LIMITED

APH ATTRIBUTES:
NG(S) ARE ISOLATED OR EMBEDDED
MBER OF NODES IS 16

EREO ATTRIBUTES: NONE
133 SEA FILE=REGISTRY SSS FUL L1

0.0% PROCESSED 489 ITERATIONS 133 ANSWERS
ARCH TIME: 00.00.02

ST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
ULL ESTIMATED COST	157.10	157.31


LE 'MEDLINE' ENTERED AT 09:15:10 ON 01 APR 2004
LE 'HCAPLUS' ENTERED AT 09:15:10 ON 01 APR 2004
SE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
LEASE SEE "HELP USAGETERMS" FOR DETAILS.
OPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'BIOSIS' ENTERED AT 09:15:10 ON 01 APR 2004
OPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)
FILE 'EMBASE' ENTERED AT 09:15:10 ON 01 APR 2004
OPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

4 0 FILE MEDLINE
5 7 FILE HCAPLUS
5 0 FILE BIOSIS
7 0 FILE EMBASE

TOTAL FOR ALL FILES
3 7 L3 AND (CANCER? OR CARCINO? OR TUMOUR OR TUMOR OR MELANOMA)

> d 1-7 cbib abs hitstr

ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN
 02:889200 Document No. 137:370090 Preparation of benzimidazolecarbamates
 for treatment of **cancer** or viral infections. Quada, James C.,
 Jr.; Agyin, Joseph K.; Camden, James Berger (The Procter & Gamble Company,
 USA). U.S. US 6482843 B1 20021119, 20 pp., Cont.-in-part of U.S. Ser. No.
 857,811. (English). CODEN: USXXAM. APPLICATION: US 2000-676407
 20000929. PRIORITY: US 1997-857811 19970516.



3 Title compds., e.g. [I; R = O2CR1; R1 = alkyl, haloalkyl, hydroxyalkyl,
 alkenyl, haloalkenyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl,
 heterocycloalkyl, (substituted) Ph, PhNH, PhCH2, etc.], were prepared. Thus,
 Me 2-amino-5-hydroxybenzimidazole carbamate and 3,5,5-trimethylhexanoyl
 chloride were stirred in THF at 23-40° to give I (R =
 O2CCH2CHMeCH2CMe3). The latter inhibited human colon **carcinoma**
 with IC50 = 15.8 µM.


T 216148-85-5P 436810-09-2P 436810-11-6P
 436810-15-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of benzimidazolecarbamates for treatment of **cancer** or
 viral infections)


N 216148-85-5 HCAPLUS

N 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
 2-(2-ethoxyethoxy)ethyl ester (9CI) (CA INDEX NAME)




N 436810-09-2 HCAPLUS

N 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
 2-(2-hydroxyethoxy)ethyl ester (9CI) (CA INDEX NAME)




N 436810-11-6 HCAPLUS

N 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
 2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)



RN 436810-15-0 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-chloro-1-(chloromethyl)ethyl ester (9CI) (CA INDEX NAME)



IT 135696-76-3 135696-78-5 216148-83-3

216148-87-7 216148-89-9 216148-90-2

436810-08-1 436810-10-5 436810-12-7

436810-13-8 436810-14-9 436810-16-1

436810-17-2 436810-18-3 436810-19-4


436810-20-7 436810-21-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(preparation of benzimidazolecarbamates for treatment of **cancer** or
viral infections)


RN 135696-76-3 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-propenyl ester (9CI) (CA INDEX NAME)








RN 135696-78-5 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
3,5,5-trimethylhexyl ester (9CI) (CA INDEX NAME)




RN 216148-83-3 HCAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
4-chlorobutyl ester (9CI) (CA INDEX NAME)




RN 436810-10-5 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
 phenylmethyl ester (9CI) (CA INDEX NAME)




RN 436810-12-7 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
 3-chloropropyl ester (9CI) (CA INDEX NAME)




RN 436810-13-8 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
 4-hydroxy-2-butenyl ester (9CI) (CA INDEX NAME)



RN 436810-14-9 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
 5-hydroxypentyl ester (9CI) (CA INDEX NAME)




RN 436810-16-1 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
 2,2,3,3,3-pentafluoropropyl ester (9CI) (CA INDEX NAME)




RN 436810-17-2 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-fluoro-1-(fluoromethyl)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-18-3 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-fluoroethyl ester (9CI) (CA INDEX NAME)




RN 436810-19-4 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-bromo-1-(bromomethyl)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-20-7 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-methylbutyl ester (9CI) (CA INDEX NAME)




RN 436810-21-8 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,7-dimethyl-6-octenyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN
2002:551611 Document No. 137:109276 Preparation of methyl 1H-benzimidazole-2-carbamates for treating **cancer** or viral infections. Camden, James Berger; Agyin, Joseph K.; Quada, James C., Jr. (The Procter & Gamble Company, USA). U.S. US 6423736 B1 20020723, 19 pp., Cont. of U.S. Ser. No. 857,811., (English). CODEN: USXXAM. APPLICATION: US 2000-676409 20000929. PRIORITY: US 1997-857811 19970516.

GI



AB The title compds. [I (R = OCOR_a; R_a = (un)substituted Ph), II (R = CONR₁R₂, CO₂R₁, OCOR₁, NHCOR₁; R₁ = alkyl, haloalkyl, cycloalkyl, etc.; R₂ = H, alkyl)] were prepared Thus, reacting Me 2-amino-5-hydroxybenzimidazolecarbamate with 3,5,5-trimethylhexanoyl chloride in THF afforded 57% I [R = OCOCH₂CHMeCH₂CMe₃] which showed IC₅₀ of 20.1 μM and IC₅₀ of 15.8 μM for growth inhibition of B16 murine **melanoma** cells and H29 human colon **cancer** cells, resp. Such compds. I may be used in combination with a chemotherapeutic agent and/or a potentiator.


IT 135696-76-3P 135696-78-5P 216148-83-3P
216148-85-5P 216148-87-7P 216148-89-9P
216148-90-2P 436810-08-1P 436810-09-2P
436810-10-5P 436810-11-6P 436810-12-7P
436810-13-8P 436810-14-9P 436810-15-0P
436810-16-1P 436810-17-2P 436810-18-3P
436810-19-4P 436810-20-7P 436810-21-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of Me benzimidazole-2-carbamates for treating **cancer** or viral infections)

RN 135696-76-3 HCAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-propenyl ester (9CI) (CA INDEX NAME)




RN 135696-78-5 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,5,5-trimethylhexyl ester (9CI) (CA INDEX NAME)




RN 216148-83-3 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 4-chlorobutyl ester (9CI) (CA INDEX NAME)



RN 216148-85-5 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(2-ethoxyethoxy)ethyl ester (9CI) (CA INDEX NAME)




RN 216148-87-7 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester (9CI) (CA INDEX NAME)




RN 216148-89-9 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
1-cyclopropylethyl ester (9CI) (CA INDEX NAME)




RN 216148-90-2 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2,4,4-trimethylpentyl ester (9CI) (CA INDEX NAME)




RN 436810-08-1 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-(2-chloroethoxy)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-09-2 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-(2-hydroxyethoxy)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-10-5 HCAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
phenylmethyl ester (9CI) (CA INDEX NAME)




RN 436810-11-6 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
 2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-12-7 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
 3-chloropropyl ester (9CI) (CA INDEX NAME)



RN 436810-13-8 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
 4-hydroxy-2-butenyl ester (9CI) (CA INDEX NAME)




RN 436810-14-9 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
 5-hydroxypentyl ester (9CI) (CA INDEX NAME)




RN 436810-15-0 HCAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-chloro-1-(chloromethyl)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-16-1 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2,2,3,3,3-pentafluoropropyl ester (9CI) (CA INDEX NAME)




RN 436810-17-2 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-fluoro-1-(fluoromethyl)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-18-3 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-fluoroethyl ester (9CI) (CA INDEX NAME)




RN 436810-19-4 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-bromo-1-(bromomethyl)ethyl ester (9CI) (CA INDEX NAME)



RN 436810-20-7 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
 2-methylbutyl ester (9CI) (CA INDEX NAME)




RN 436810-21-8 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
 3,7-dimethyl-6-octenyl ester (9CI) (CA INDEX NAME)




L8 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN
 2002:551610 Document No. 137:109275 Preparation of methyl
 1H-benzimidazole-2-carbamates for treating **cancer** or viral
 infections. Camden, James Berger; Quada, James C., Jr.; Agyin, Joseph K.
 (The Procter & Gamble Company, USA). U.S. US 6423735 B1 20020723, 17 pp.,
 Cont. of U.S. Ser. No. 857,811. (English). CODEN: USXXAM. APPLICATION:
 US 2000-676029 20000929. PRIORITY: US 1997-857811 19970516.

GI



I



II

AB The title compds. [I (R = OCORa; Ra = (un)substituted Ph), II (R =
 CONR1R2, CO2R1, OCOR1, NHCOR1; R1 = alkyl, haloalkyl, cycloalkyl, etc.; R2
 = H, alkyl)] were prepared. Thus, reacting Me 2-amino-5-
 hydroxybenzimidazolecarbamate with 3,5,5-trimethylhexanoyl chloride in THF
 afforded 57% I [R = OCOCH2CHMeCH2CMe3] which showed IC50 of 20.1 μ M and
 IC50 of 15.8 μ M for growth inhibition of B16 murine **melanoma**
 cells and H29 human colon **cancer** cells, resp. Such compds. I

may be used in combination with a chemotherapeutic agent and/or a potentiator such as DNA-interactive agent, an antimetabolite, a tubulin-interactive agent, a hormonal agent, an antihormonal antigen, and an adrenal corticosteroid.


IT 135696-76-3P 135696-78-5P 216148-83-3P
 216148-85-5P 216148-87-7P 216148-89-9P
 216148-90-2P 436810-08-1P 436810-09-2P
 436810-10-5P 436810-11-6P 436810-12-7P
 436810-13-8P 436810-14-9P 436810-15-0P
 436810-16-1P 436810-17-2P 436810-18-3P
 436810-19-4P 436810-20-7P 436810-21-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of Me benzimidazole-2-carbamates for treating cancer or viral infections)


RN 135696-76-3 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-propenyl ester (9CI) (CA INDEX NAME)




RN 135696-78-5 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,5,5-trimethylhexyl ester (9CI) (CA INDEX NAME)




RN 216148-83-3 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 4-chlorobutyl ester (9CI) (CA INDEX NAME)




RN 216148-85-5 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(2-ethoxyethoxy)ethyl ester (9CI) (CA INDEX NAME)




RN 216148-87-7 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester (9CI) (CA INDEX NAME)




RN 216148-89-9 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 1-cyclopropylethyl ester (9CI) (CA INDEX NAME)




RN 216148-90-2 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2,4,4-trimethylpentyl ester (9CI) (CA INDEX NAME)




RN 436810-08-1 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(2-chloroethoxy)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-09-2 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-(2-hydroxyethoxy)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-10-5 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
phenylmethyl ester (9CI) (CA INDEX NAME)




RN 436810-11-6 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-12-7 HCAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
3-chloropropyl ester (9CI) (CA INDEX NAME)




RN 436810-13-8 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
4-hydroxy-2-butenyl ester (9CI) (CA INDEX NAME)







RN 436810-14-9 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 5-hydroxypentyl ester (9CI) (CA INDEX NAME)




RN 436810-15-0 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-chloro-1-(chloromethyl)ethyl ester (9CI) (CA INDEX NAME)



RN 436810-16-1 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2,2,3,3,3-pentafluoropropyl ester (9CI) (CA INDEX NAME)




RN 436810-17-2 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-fluoro-1-(fluoromethyl)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-18-3 HCAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-fluoroethyl ester (9CI) (CA INDEX NAME)




RN 436810-19-4 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-bromo-1-(bromomethyl)ethyl ester (9CI) (CA INDEX NAME)



RN 436810-20-7 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-methylbutyl ester (9CI) (CA INDEX NAME)




RN 436810-21-8 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
3,7-dimethyl-6-octenyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN
2002:534039 Document No. 137:93753 Preparation of 2,5-disubstituted
benzimidazoles used in the treatment of **cancer** or viral
infections. Camden, James Berger; Agyin, Joseph K.; Quada, James C., Jr.
(The Procter & Gamble Company, USA). U.S. US 6420411 B1 20020716, 18 pp.,
Cont.-in-part of U. S. Ser. No. 857,811. (English). CODEN: USXXAM.
APPLICATION: US 2000-676202 20000929. PRIORITY: US 1997-857811 19970516.

GI




AB Title compds. I [R1 = (halo)alkyl, hydroxyalkyl, (halo)alkenyl, cycloalkyl, heterocycloalkyl, substituted Ph and analogs thereof] were prepared. For instance, Me 5-amino-1H-benzimidazol-2-ylcarbamate was acylated with 3,5,5-trimethylhexanoyl chloride to provide I (R1 = CH₂CH(CH₃)CH₂C(CH₃)₃; II). II had IC₅₀ = 6.6 and 7.0 μM for the murine melanoma and human colon carcinoma cell line resp. I are used for the treatment of cancers or viral infections and may be used in combination with a chemotherapeutic agent and/or a potentiator.

IT 135696-76-3P, 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-propenyl ester 135696-78-5P, 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,5,5-trimethylhexyl ester 216148-83-3P, 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 4-chlorobutyl ester 216148-85-5P, 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(2-ethoxyethoxy)ethyl ester 216148-87-7P, 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester 216148-89-9P, 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 1-cyclopropylethyl ester 216148-90-2P, 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2,4,4-trimethylpentyl ester 436810-08-1P 436810-09-2P, 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(2-hydroxyethoxy)ethyl ester 436810-10-5P 436810-11-6P, 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(dimethylamino)ethyl ester 436810-12-7P, 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-chloropropyl ester 436810-13-8P 436810-14-9P, 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 5-hydroxypentyl ester 436810-15-0P 436810-16-1P, 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2,2,3,3,3-pentafluoropropyl ester 436810-17-2P, 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-fluoro-1-(fluoromethyl)ethyl ester 436810-18-3P 436810-19-4P 436810-20-7P 436810-21-8P, 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,7-dimethyl-6-octenyl ester
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug; preparation of substituted benzimidazole-2-carbamates as antiviral/antitumor agents)


RN 135696-76-3 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-propenyl ester (9CI) (CA INDEX NAME)




RN 135696-78-5 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
3,5,5-trimethylhexyl ester (9CI) (CA INDEX NAME)




RN 216148-83-3 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
4-chlorobutyl ester (9CI) (CA INDEX NAME)




RN 216148-85-5 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-(2-ethoxyethoxy)ethyl ester (9CI) (CA INDEX NAME)




RN 216148-87-7 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl
ester (9CI) (CA INDEX NAME)




RN 216148-89-9 HCAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
1-cyclopropylethyl ester (9CI) (CA INDEX NAME)




RN 216148-90-2 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
 2,4,4-trimethylpentyl ester (9CI) (CA INDEX NAME)




RN 436810-08-1 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
 2-(2-chloroethoxy)ethyl ester (9CI) (CA INDEX NAME)



RN 436810-09-2 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
 2-(2-hydroxyethoxy)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-10-5 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
 phenylmethyl ester (9CI) (CA INDEX NAME)




RN 436810-11-6 HCAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-12-7 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
3-chloropropyl ester (9CI) (CA INDEX NAME)




RN 436810-13-8 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
4-hydroxy-2-butenyl ester (9CI) (CA INDEX NAME)




RN 436810-14-9 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
5-hydroxypentyl ester (9CI) (CA INDEX NAME)




RN 436810-15-0 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-chloro-1-(chloromethyl)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-16-1 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2,2,3,3,3-pentafluoropropyl ester (9CI) (CA INDEX NAME)




RN 436810-17-2 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-fluoro-1-(fluoromethyl)ethyl ester (9CI) (CA INDEX NAME)



RN 436810-18-3 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-fluoroethyl ester (9CI) (CA INDEX NAME)




RN 436810-19-4 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-bromo-1-(bromomethyl)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-20-7 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-methylbutyl ester (9CI) (CA INDEX NAME)



RN 436810-21-8 HCAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
3,7-dimethyl-6-octenyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN

2002:461292 Document No. 137:33301 Preparation of 2,5-disubstituted
benzimidazoles used in the treatment of **cancer** or viral
infections. Quada, James C., Jr.; Agyin, Joseph K.; Camden, James Berger
(The Procter & Gamble Company, USA). U.S. US 6407131 B1 20020618, 18 pp.,
Cont.-in-part of U.S. Ser. No. 857,811. (English). CODEN: USXXAM.
APPLICATION: US 2000-676030 20000929. PRIORITY: US 1997-857811 19970516.

GI



AB Title compds. I [R1 = (halo)alkyl, hydroxyalkyl, (halo)alkenyl,
cycloalkyl, heterocycloalkyl, substituted Ph and analogs thereof] were
prepared For instance, Me 2-amino-5-hydroxybenzimidazole carbamate was
acylated with 3,5,5-trimethylhexanoyl chloride to provide I (R1 =
CH2CH2CH(CH3)CH2C(CH3)3; II). II had IC50 = 20.1 and 15.8 μ M for the
murine **melanoma** and human colon **carcinoma** cell line
resp. I are used for the treatment of **cancers** or viral
infections and may be used in combination with a chemotherapeutic agent
and/or a potentiator.

IT 135696-76-3P 135696-78-5P 216148-83-3P
216148-85-5P 216148-87-7P 216148-89-9P
216148-90-2P 436810-08-1P 436810-09-2P
436810-10-5P 436810-11-6P 436810-12-7P
436810-13-8P 436810-14-9P 436810-15-0P
436810-16-1P 436810-17-2P 436810-18-3P
436810-19-4P 436810-20-7P 436810-21-8P


RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(drug; preparation of substituted benzimidazole-2-carbamates as
antiviral/antitumor agents)


RN 135696-76-3 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-propenyl ester (9CI) (CA INDEX NAME)




RN 135696-78-5 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
3,5,5-trimethylhexyl ester (9CI) (CA INDEX NAME)




RN 216148-83-3 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
4-chlorobutyl ester (9CI) (CA INDEX NAME)




RN 216148-85-5 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-(2-ethoxyethoxy)ethyl ester (9CI) (CA INDEX NAME)




RN 216148-87-7 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl
ester (9CI) (CA INDEX NAME)




RN 216148-89-9 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 1-cyclopropylethyl ester (9CI) (CA INDEX NAME)




RN 216148-90-2 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2,4,4-trimethylpentyl ester (9CI) (CA INDEX NAME)




RN 436810-08-1 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(2-chloroethoxy)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-09-2 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(2-hydroxyethoxy)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-10-5 HCAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
phenylmethyl ester (9CI) (CA INDEX NAME)




RN 436810-11-6 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-12-7 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
3-chloropropyl ester (9CI) (CA INDEX NAME)



RN 436810-13-8 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
4-hydroxy-2-butenyl ester (9CI) (CA INDEX NAME)




RN 436810-14-9 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
5-hydroxypentyl ester (9CI) (CA INDEX NAME)




RN 436810-15-0 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-chloro-1-(chloromethyl)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-16-1 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2,2,3,3,3-pentafluoropropyl ester (9CI) (CA INDEX NAME)




RN 436810-17-2 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-fluoro-1-(fluoromethyl)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-18-3 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-fluoroethyl ester (9CI) (CA INDEX NAME)




RN 436810-19-4 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-bromo-1-(bromomethyl)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-20-7 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-methylbutyl ester (9CI) (CA INDEX NAME)



RN 436810-21-8 HCAPLUS



CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
3,7-dimethyl-6-octenyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN

2002:408648 Document No. 137:6176 Preparation of aromatic acid derivatives
useful as serine protease inhibitors. Bisacchi, Gregory S.; Sutton, James
C., Jr.; Slusarchyk, William A.; Treuner, Uwe D.; Zhao, Guohua; Cheney,
Daniel L.; Wu, Shung C.; Shi, Yan (Bristol-Myers Squibb Company, USA).
PCT Int. Appl. WO 2002042273 A2 20020530, 182 pp. DESIGNATED STATES: W:
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR,
CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID,
IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG,
KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK,
ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD,
TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US46884
20011107. PRIORITY: US 2000-PV246392 20001107.

GI



AB Aromatic compds. I, are useful as serine protease inhibitors, wherein ring B is Ph or pyridyl; W is amide, alkyl, alkenyl, heterocycle, heteroaryl, aryl, cycloalkyl; L is a linker group; X is N, CH, or C, provided that X is C when R1 and R2 join to form a fully unsatd. ring; Z is an optionally-substituted monocyclic or bicyclic ring system; R is H, alkoxy, amine, alkyl, alkenyl, halogen, haloalkyl, cyano, nitro, alkylthio, CHO, acyl, CO2H, alkoxycarbonyl, sulfonamido, sulfonyl, Ph; R1 and R2 (i) are independently selected from hydrogen, alkyl, alkenyl, heteroaryl, aryl, heterocycle, and cycloalkyl; or (ii) are taken together to form an aryl, heteroaryl, cycloalkyl, or heterocycle, provided that R1 and R2 do not together form pyrazole when W is methoxy and Z is biphenyl; and when R1 and R2 individually or together form a heteroaryl, aryl, heterocycle, cycloalkyl; R3 is hydrogen, alkyl, substituted alkyl, heteroaryl, aryl, heterocycle, cycloalkyl, or alkyl substituted with -OC(O)R4 or -OC(O)OR4, wherein R4 is alkyl, cycloalkyl, provided that R3 is not Ph when W is methoxy. Thus, II was prepared for treating a coagulation-associated disorder, an inflammatory or immune disease, or metastases (no data). Included within the scope of the invention are pharmaceutical compns. for treating a serine protease disease, an inflammatory or immune condition, or **cancer**.


IT **218301-15-6**

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of aromatic acid derivs. useful as anti-inflammatory, anticoagulant, antitumor, immunomodulator agents and serine protease inhibitors)


RN 218301-15-6 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[[[(phenylmethoxy)carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN
 1998:764283 Document No. 130:20597 Benzimidazole-2-carbamates for the
 treatment of viral infections and **cancer**. Camden, James Berger
 (The Procter & Gamble Company, USA). PCT Int. Appl. WO 9851304 A1
 19981119, 24 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG,
 BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS,
 JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,
 MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA,
 UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF,
 BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC,
 ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2.
 APPLICATION: WO 1997-US21565 19971126. PRIORITY: US 1997-857811 19970516.

GI




AB A pharmaceutical composition that is effective in the treatment of HIV and
 other viral infections and inhibits growth of **cancers** and
tumors in mammals comprises a benzimidazole derivative (I; R = H,
 CO₂H, OH, NH₂, CO₂R₁; R₁ = alkoxy, haloalkyl, alkenyl, cycloalkyl), the
 pharmaceutically acceptable salts thereof, or mixts. thereof. I (R = H)
 inhibits the growth of B16 murine **melanoma** and HT29 human colon
carcinoma cells with IC₅₀ of 4.925 and 3.297 μM, resp.

IT 216148-83-3 216148-85-5 216148-87-7
 216148-88-8 216148-89-9 216148-90-2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (benzimidazole-2-carbamates for treatment of **cancer** and viral
 infections)


RN 216148-83-3 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
 4-chlorobutyl ester (9CI) (CA INDEX NAME)




RN 216148-85-5 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-(2-ethoxyethoxy)ethyl ester (9CI) (CA INDEX NAME)




RN 216148-87-7 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl
ester (9CI) (CA INDEX NAME)




RN 216148-88-8 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
3,3,7-trimethyl-6-octenyl ester (9CI) (CA INDEX NAME)




RN 216148-89-9 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
1-cyclopropylethyl ester (9CI) (CA INDEX NAME)



RN 216148-90-2 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2,4,4-trimethylpentyl ester (9CI) (CA INDEX NAME)




IT 216148-91-3 216148-94-6 216148-95-7
 216148-96-8 216148-98-0 216149-00-7
 216149-02-9 216149-09-6 216149-10-9
 216149-11-0 216149-13-2 216149-14-3
 216149-16-5 216149-17-6 216149-18-7
 216149-19-8 216149-20-1 216149-21-2
 216149-22-3 216149-23-4 216149-27-8
 216149-29-0 216149-31-4 216149-33-6
 216149-35-8 216149-37-0 216149-43-8
 216149-45-0 216149-47-2 216149-53-0
 216149-56-3 216149-59-6 216149-62-1
 216149-69-8 216149-72-3 216149-74-5
 216149-77-8 216149-81-4 216149-84-7
 216149-85-8 216149-87-0 216149-88-1
 216149-91-6 216149-92-7 216149-95-0
 216149-96-1 216149-98-3 216149-99-4
 216150-01-5 216150-02-6 216150-03-7
 216150-04-8 216150-06-0 216150-07-1
 216150-08-2 216150-09-3 216150-10-6
 216150-12-8 216150-17-3 216150-19-5
 216150-20-8 216150-21-9 216150-22-0
 216150-23-1 216150-27-5 216150-28-6
 216150-30-0 216150-31-1 216150-32-2
 216150-34-4 216150-35-5 216150-40-2
 216150-41-3 216150-42-4 216150-43-5
 216150-44-6 216150-45-7 216150-46-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(benzimidazole-2-carbamates for treatment of **cancer** and viral infections)

RN 216148-91-3 HCAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 4-chlorobutyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 216148-94-6 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 4-chlorobutyl ester, monohydrobromide (9CI) (CA INDEX NAME)




● HBr

RN 216148-95-7 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
 4-chlorobutyl ester, sulfate (9CI) (CA INDEX NAME)


CM 1

CRN 216148-83-3
 CMF C14 H16 Cl N3 O4



CM 2


CRN 7664-93-9
 CMF H2 O4 S



RN 216148-96-8 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
 4-chlorobutyl ester, mononitrate (9CI) (CA INDEX NAME)

CM 1


CRN 216148-83-3
 CMF C14 H16 Cl N3 O4



CM 2

CRN 7697-37-2

CMF H N O3




RN 216148-98-0 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 4-chlorobutyl ester, phosphate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-83-3


CMF C14 H16 Cl N3 O4



CM 2

CRN 7664-38-2

CMF H3 O4 P




RN 216149-00-7 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 4-chlorobutyl ester, monoformate (9CI) (CA INDEX NAME)

CM 1


CRN 216148-83-3

CMF C14 H16 Cl N3 O4



CM 2


CRN 64-18-6
CMF C H2 O2



RN 216149-02-9 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
4-chlorobutyl ester, (2R,3R)-2,3-dihydroxybutanedioate (9CI) (CA INDEX
NAME)

CM 1


CRN 216148-83-3
CMF C14 H16 Cl N3 O4



CM 2

CRN 87-69-4
CMF C4 H6 O6


Absolute stereochemistry.



RN 216149-09-6 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
4-chlorobutyl ester, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-83-3
CMF C14 H16 Cl N3 O4




Searched by: Mary Hale 571-272-2507 REM 1D86

CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 216149-10-9 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 4-chlorobutyl ester, 2-hydroxy-1,2,3-propanetricarboxylate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-83-3


CMF C14 H16 Cl N3 O4



CM 2

CRN 77-92-9

CMF C6 H8 O7




RN 216149-11-0 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 4-chlorobutyl ester, monobenzoate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-83-3


CMF C14 H16 Cl N3 O4



CM 2

CRN 65-85-0

CMF C7 H6 O2




RN 216149-13-2 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 4-chlorobutyl ester, mono(2-hydroxybenzoate) (9CI) (CA INDEX NAME)

CM 1

CRN 216148-83-3


CMF C14 H16 Cl N3 O4



CM 2

CRN 69-72-7

CMF C7 H6 O3




RN 216149-14-3 HCAPLUS

CN L-Ascorbic acid, compd. with 4-chlorobutyl 2-[(methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-83-3

CMF C14 H16 Cl N3 O4




CM 2

CRN 50-81-7

CMF C6 H8 O6

Absolute stereochemistry.




RN 216149-16-5 HCAPLUS

CN Butanedioic acid, hydroxy-, compd. with 4-chlorobutyl 2-[(methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-83-3


CMF C14 H16 Cl N3 O4



CM 2

CRN 6915-15-7

CMF C4 H6 O5




RN 216149-17-6 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,


Searched by: Mary Hale 571-272-2507 REM 1D86

2-(2-ethoxyethoxy)ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 216149-18-7 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-(2-ethoxyethoxy)ethyl ester, monohydrobromide (9CI) (CA INDEX NAME)




● HBr

RN 216149-19-8 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-(2-ethoxyethoxy)ethyl ester, sulfate (9CI) (CA INDEX NAME)


CM 1

CRN 216148-85-5
CMF C16 H21 N3 O6



CM 2

CRN 7664-93-9
CMF H2 O4 S




RN 216149-20-1 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-(2-ethoxyethoxy)ethyl ester, mononitrate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-85-5


CMF C16 H21 N3 O6



CM 2

CRN 7697-37-2

CMF H N O3




RN 216149-21-2 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-(2-ethoxyethoxy)ethyl ester, phosphate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-85-5


CMF C16 H21 N3 O6



CM 2

CRN 7664-38-2


CMF H3 O4 P



RN 216149-22-3 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
 2-(2-ethoxyethoxy)ethyl ester, monoformate (9CI) (CA INDEX NAME)


CM 1

CRN 216148-85-5
 CMF C16 H21 N3 O6



CM 2


CRN 64-18-6
 CMF C H2 O2



RN 216149-23-4 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
 2-(2-ethoxyethoxy)ethyl ester, (2R,3R)-2,3-dihydroxybutanedioate (9CI)
 (CA INDEX NAME)

CM 1

CRN 216148-85-5
 CMF C16 H21 N3 O6




CM 2

CRN 87-69-4
 CMF C4 H6 O6

Absolute stereochemistry.


Searched by: Mary Hale 571-272-2507 REM 1D86



RN 216149-27-8 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
 2-(2-ethoxyethoxy)ethyl ester, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1


CRN 216148-85-5
 CMF C16 H21 N3 O6



CM 2

CRN 110-16-7
 CMF C4 H4 O4


Double bond geometry as shown.



RN 216149-29-0 HCAPLUS
 CN Butanedioic acid, hydroxy-, compd. with 2-(2-ethoxyethoxy)ethyl
 2-[(methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (9CI) (CA INDEX
 NAME)

CM 1


CRN 216148-85-5
 CMF C16 H21 N3 O6



CM 2

Searched by: Mary Hale 571-272-2507 REM 1D86


CRN 6915-15-7
CMF C4 H6 O5



RN 216149-31-4 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-(2-ethoxyethoxy)ethyl ester, 2-hydroxy-1,2,3-propanetricarboxylate (9CI)
(CA INDEX NAME)


CM 1

CRN 216148-85-5
CMF C16 H21 N3 O6



CM 2


CRN 77-92-9
CMF C6 H8 O7



RN 216149-33-6 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-(2-ethoxyethoxy)ethyl ester, monobenzoate (9CI) (CA INDEX NAME)


CM 1

CRN 216148-85-5
CMF C16 H21 N3 O6



CM 2


CRN 65-85-0
CMF C7 H6 O2



RN 216149-35-8 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-(2-ethoxyethoxy)ethyl ester, mono(2-hydroxybenzoate) (9CI) (CA INDEX
NAME)


CM 1

CRN 216148-85-5
CMF C16 H21 N3 O6



CM 2


CRN 69-72-7
CMF C7 H6 O3



RN 216149-37-0 HCAPLUS
CN L-Ascorbic acid, compd. with 2-(2-ethoxyethoxy)ethyl 2-
[(methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (9CI) (CA INDEX
NAME)

CM 1


CRN 216148-85-5
CMF C16 H21 N3 O6




CM 2

CRN 50-81-7
CMF C6 H8 O6

Absolute stereochemistry.




RN 216149-43-8 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester, monohydrochloride (9CI) (CA.INDEX NAME)



● HCl

RN 216149-45-0 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 216149-47-2 HCAPLUS


Searched by: Mary Hale 571-272-2507 REM 1D86

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester, sulfate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-87-7


CMF C14 H15 N3 O4



CM 2

CRN 7664-93-9

CMF H2 O4 S




RN 216149-53-0 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester, mononitrate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-87-7


CMF C14 H15 N3 O4



CM 2

CRN 7697-37-2

CMF H N O3



RN 216149-56-3 HCAPLUS


Searched by: Mary Hale 571-272-2507 REM 1D86

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester, phosphate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-87-7


CMF C14 H15 N3 O4



CM 2

CRN 7664-38-2

CMF H3 O4 P




RN 216149-59-6 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-87-7

CMF C14 H15 N3 O4



CM 2

CRN 64-18-6

CMF C H2 O2




RN 216149-62-1 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester, (2R,3R)-2,3-dihydroxybutanedioate (9CI) (CA INDEX NAME)

CM 1


CRN 216148-87-7
CMF C14 H15 N3 O4



CM 2

CRN 87-69-4
CMF C4 H6 O6


Absolute stereochemistry.



RN 216149-69-8 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1


CRN 216148-87-7
CMF C14 H15 N3 O4



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




Searched by: Mary Hale 571-272-2507 REM 1D86

RN 216149-72-3 HCAPLUS
CN Butanedioic acid, hydroxy-, compd. with 3-butenyl 2-
[(methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (9CI) (CA INDEX
NAME)


CM 1

CRN 216148-87-7
CMF C14 H15 N3 O4



CM 2


CRN 6915-15-7
CMF C4 H6 O5



RN 216149-74-5 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl
ester, 2-hydroxy-1,2,3-propanetricarboxylate (9CI) (CA INDEX NAME)


CM 1

CRN 216148-87-7
CMF C14 H15 N3 O4



CM 2


CRN 77-92-9
CMF C6 H8 O7



RN 216149-77-8 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester, monobenzoate (9CI) (CA INDEX NAME)


CM 1

CRN 216148-87-7
 CMF C14 H15 N3 O4



CM 2


CRN 65-85-0
 CMF C7 H6 O2



RN 216149-81-4 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester, mono(2-hydroxybenzoate) (9CI) (CA INDEX NAME)


CM 1

CRN 216148-87-7
 CMF C14 H15 N3 O4



CM 2


CRN 69-72-7
CMF C7 H6 O3



RN 216149-84-7 HCAPLUS
CN L-Ascorbic acid, compd. with 3-butenyl 2-[(methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (9CI) (CA INDEX NAME)

CM 1


CRN 216148-87-7
CMF C14 H15 N3 O4




CM 2

CRN 50-81-7
CMF C6 H8 O6

Absolute stereochemistry.




RN 216149-85-8 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,3,7-trimethyl-6-octenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

Searched by: Mary Hale 571-272-2507 REM 1D86

RN 216149-87-0 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
 3,3,7-trimethyl-6-octenyl ester, monohydrobromide (9CI) (CA INDEX NAME)




● HBr

RN 216149-88-1 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
 3,3,7-trimethyl-6-octenyl ester, sulfate (9CI) (CA INDEX NAME)


CM 1

CRN 216148-88-8
 CMF C21 H29 N3 O4



CM 2


CRN 7664-93-9
 CMF H2 O4 S



RN 216149-91-6 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
 3,3,7-trimethyl-6-octenyl ester, mononitrate (9CI) (CA INDEX NAME)

CM 1


CRN 216148-88-8
 CMF C21 H29 N3 O4



CM 2

CRN 7697-37-2

CMF H N O3




RN 216149-92-7 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,3,7-trimethyl-6-octenyl ester, phosphate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-88-8


CMF C21 H29 N3 O4



CM 2

CRN 7664-38-2

CMF H3 O4 P




RN 216149-95-0 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,3,7-trimethyl-6-octenyl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-88-8


CMF C21 H29 N3 O4



CM 2

CRN 64-18-6

CMF C H2 O2




RN 216149-96-1 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,3,7-trimethyl-6-octenyl ester, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-88-8

CMF C21 H29 N3 O4




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 216149-98-3 HCAPLUS

CN Butanedioic acid, hydroxy-, compd. with 3,3,7-trimethyl-6-octenyl 2-[(methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-88-8


CMF C21 H29 N3 O4



CM 2

CRN 6915-15-7

CMF C4 H6 O5




RN 216149-99-4 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,3,7-trimethyl-6-octenyl ester, 2-hydroxy-1,2,3-propanetricarboxylate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-88-8


CMF C21 H29 N3 O4



CM 2

CRN 77-92-9

CMF C6 H8 O7




RN 216150-01-5 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,3,7-trimethyl-6-octenyl ester, monobenzoate (9CI) (CA INDEX NAME)

CM 1


CRN 216148-88-8

CMF C21 H29 N3 O4



CM 2


CRN 65-85-0
CMF C7 H6 O2



RN 216150-02-6 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,3,7-trimethyl-6-octenyl ester, mono(2-hydroxybenzoate) (9CI) (CA INDEX NAME)


CM 1

CRN 216148-88-8
CMF C21 H29 N3 O4



CM 2

CRN 69-72-7
CMF C7 H6 O3




RN 216150-03-7 HCAPLUS
CN L-Ascorbic acid, compd. with 3,3,7-trimethyl-6-octenyl 2-[(methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-88-8

CMF C21 H29 N3 O4




CM 2

CRN 50-81-7


CMF C6 H8 O6

Absolute stereochemistry.



RN 216150-04-8 HCAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
1-cyclopropylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 216150-06-0 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
1-cyclopropylethyl ester, monohydrobromide (9CI) (CA INDEX NAME)




● HBr

RN 216150-07-1 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
 1-cyclopropylethyl ester, sulfate (9CI) (CA INDEX NAME)


CM 1

CRN 216148-89-9
 CMF C15 H17 N3 O4



CM 2


CRN 7664-93-9
 CMF H2 O4 S



RN 216150-08-2 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
 1-cyclopropylethyl ester, mononitrate (9CI) (CA INDEX NAME)

CM 1


CRN 216148-89-9
 CMF C15 H17 N3 O4



CM 2

CRN 7697-37-2

CMF H N O3




RN 216150-09-3 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 1-cyclopropylethyl ester, phosphate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-89-9


CMF C15 H17 N3 O4



CM 2

CRN 7664-38-2

CMF H3 O4 P




RN 216150-10-6 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 1-cyclopropylethyl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-89-9


CMF C15 H17 N3 O4



CM 2

CRN 64-18-6

CMF C H2 O2




RN 216150-12-8 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
1-cyclopropylethyl ester, (2R,3R)-2,3-dihydroxybutanedioate (9CI) (CA
INDEX NAME)

CM 1

CRN 216148-89-9

CMF C15 H17 N3 O4




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.




RN 216150-17-3 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
1-cyclopropylethyl ester, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-89-9

CMF C15 H17 N3 O4




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 216150-19-5 HCAPLUS

CN Butanedioic acid, hydroxy-, compd. with 1-cyclopropylethyl
2-[(methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (9CI) (CA INDEX
NAME)

CM 1

CRN 216148-89-9


CMF C15 H17 N3 O4



CM 2

CRN 6915-15-7

CMF C4 H6 O5




RN 216150-20-8 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
1-cyclopropylethyl ester, 2-hydroxy-1,2,3-propanetricarboxylate (9CI) (CA
INDEX NAME)

CM 1


CRN 216148-89-9

CMF C15 H17 N3 O4



CM 2


CRN 77-92-9
CMF C6 H8 O7



RN 216150-21-9 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
1-cyclopropylethyl ester, monobenzoate (9CI) (CA INDEX NAME)


CM 1

CRN 216148-89-9
CMF C15 H17 N3 O4



CM 2

CRN 65-85-0
CMF C7 H6 O2




RN 216150-22-0 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
1-cyclopropylethyl ester, mono(2-hydroxybenzoate) (9CI) (CA INDEX NAME)

CM 1

CRN 216148-89-9


CMF C15 H17 N3 O4



CM 2

CRN 69-72-7

CMF C7 H6 O3




RN 216150-23-1 HCAPLUS

CN L-Ascorbic acid, compd. with 1-cyclopropylethyl 2-[(methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 216148-89-9

CMF C15 H17 N3 O4




CM 2

CRN 50-81-7


CMF C6 H8 O6

Absolute stereochemistry.




Searched by: Mary Hale 571-272-2507 REM 1D86

RN 216150-27-5 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2,4,4-trimethylpentyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 216150-28-6 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2,4,4-trimethylpentyl ester, monohydrobromide (9CI) (CA INDEX NAME)




● HBr

RN 216150-30-0 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2,4,4-trimethylpentyl ester, sulfate (9CI) (CA INDEX NAME)


CM 1

CRN 216148-90-2
CMF C18 H25 N3 O4



CM 2


CRN 7664-93-9
CMF H2 O4 S



RN 216150-31-1 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
 2,4,4-trimethylpentyl ester, mononitrate (9CI) (CA INDEX NAME)


CM 1

CRN 216148-90-2
 CMF C18 H25 N3 O4



CM 2


CRN 7697-37-2
 CMF H N O3



RN 216150-32-2 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
 2,4,4-trimethylpentyl ester, phosphate (9CI) (CA INDEX NAME)


CM 1

CRN 216148-90-2
 CMF C18 H25 N3 O4



CM 2


CRN 7664-38-2
 CMF H3 O4 P



RN 216150-34-4 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
 2,4,4-trimethylpentyl ester, monoformate (9CI) (CA INDEX NAME)


CM 1

CRN 216148-90-2
 CMF C18 H25 N3 O4



CM 2


CRN 64-18-6
 CMF C H2 O2



RN 216150-35-5 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
 2,4,4-trimethylpentyl ester, (2R,3R)-2,3-dihydroxybutanedioate (9CI) (CA
 INDEX NAME)

CM 1

CRN 216148-90-2
 CMF C18 H25 N3 O4




CM 2

CRN 87-69-4
 CMF C4 H6 O6

Absolute stereochemistry.


Searched by: Mary Hale 571-272-2507 REM 1D86



RN 216150-40-2 HCAPLUS
 CN Butanedioic acid, hydroxy-, compd. with 2,4,4-trimethylpentyl
 2-[(methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (9CI) (CA INDEX
 NAME)


CM 1

CRN 216148-90-2
 CMF C18 H25 N3 O4



CM 2


CRN 6915-15-7
 CMF C4 H6 O5



RN 216150-41-3 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
 2,4,4-trimethylpentyl ester, 2-hydroxy-1,2,3-propanetricarboxylate (9CI)
 (CA INDEX NAME)


CM 1

CRN 216148-90-2
 CMF C18 H25 N3 O4



CM 2


CRN 77-92-9
CMF C6 H8 O7



RN 216150-42-4 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2,4,4-trimethylpentyl ester, monobenzoate (9CI) (CA INDEX NAME)


CM 1

CRN 216148-90-2
CMF C18 H25 N3 O4



CM 2


CRN 65-85-0
CMF C7 H6 O2



RN 216150-43-5 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2,4,4-trimethylpentyl ester, mono(2-hydroxybenzoate) (9CI) (CA INDEX
NAME)


CM 1

CRN 216148-90-2
CMF C18 H25 N3 O4



CM 2


CRN 69-72-7
CMF C7 H6 O3



RN 216150-44-6 HCAPLUS
CN L-Ascorbic acid, compd. with 2,4,4-trimethylpentyl 2-
[(methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (9CI) (CA INDEX
NAME)

CM 1


CRN 216148-90-2
CMF C18 H25 N3 O4



CM 2

CRN 50-81-7
CMF C6 H8 O6


Absolute stereochemistry.



RN 216150-45-7 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2,4,4-trimethylpentyl ester, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1


CRN 216148-90-2
CMF C18 H25 N3 O4



CM 2

CRN 110-16-7
CMF C4 H4 O4


Double bond geometry as shown.



RN 216150-46-8 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
3,3,7-trimethyl-6-octenyl ester, (2R,3R)-2,3-dihydroxybutanedioate (9CI)
(CA INDEX NAME)

CM 1


CRN 216148-88-8
CMF C21 H29 N3 O4



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



=> s 13 and (pharmac? or compos?)
L9 0 FILE MEDLINE

Searched by: Mary Hale 571-272-2507 REM 1D86

L10 3 FILE HCAPLUS
L11 0 FILE BIOSIS
L12 0 FILE EMBASE

TOTAL FOR ALL FILES

L13 3 L3 AND (PHARMAC? OR COMPOS?)

=> s l13 not l8

L14 0 FILE MEDLINE
L15 1 FILE HCAPLUS
L16 0 FILE BIOSIS
L17 0 FILE EMBASE

TOTAL FOR ALL FILES

L18 1 L13 NOT L8

=> d cbib abs hitstr

L18 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN

1994:124172 Document No. 120:124172 Segregation of activity profile in benzimidazoles: effect of spacers at 5(6)-position of methyl benzimidazole-2-carbamates. Agarwal, Shiv K.; Sharma, Satyavan; Bhaduri, A. P. (Med. Chem. Div., Cent. Drug Res. Inst., Lucknow, 226001, India). Zeitschrift fuer Naturforschung, C: Journal of Biosciences, 48(11-12), 829-38 (English) 1993. CODEN: ZNCBDA. ISSN: 0341-0382.

AB The design and synthesis of a series of Me 5(6)-substituted benzimidazole-2-carbamates as potential anthelmintics are described. A rational anal. of the structural parameters which segregate the activity of resulting benzimidazole-2-carbamates against enteric and tissue dwelling helminths is presented. The influence of single and multiple spacers, which link the **pharmacophores** at 5(6)-position of benzimidazole-2-carbamate, on the activity against *Ancylostoma ceylanicum* (hookworm), *Syphacia obvelata* (pinworm), *Hymenolepis nana* (tapeworm) *Litomosoides carinii* and *Acanthocheilonema viteae* (filarial worm) has been presented. This anal. indicates that for activity against intestinal helminth the presence of one spacer holding the **pharmacophore** approx. 3 Å apart from the parent nucleus is usually preferred. While for activity against tissue dwelling parasite, the repetition of the benzimidazole-2-carbamate nucleus joined together through the 5,5'-position with one spacer kept apart by distance of 3 Å unit is usually desired.


IT 121649-63-6 121649-65-8 121649-66-9
153213-39-9 153213-40-2 153213-41-3
153213-42-4

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(anthelmintic activity of, structure-activity relations in)

RN 121649-63-6 HCAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 121649-65-8 HCAPLUS


Searched by: Mary Hale 571-272-2507 REM 1D86

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, propyl ester (9CI) (CA INDEX NAME)




RN 121649-66-9 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 153213-39-9 HCAPLUS

CN Carbamic acid, [5-[[[(4-benzoyl-1-piperazinyl)oxy]carbonyl]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 153213-40-2 HCAPLUS

CN Carbamic acid, [5-[[[4-(2-furanylcarbonyl)-1-piperazinyl]oxy]carbonyl]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 153213-41-3 HCAPLUS

CN Carbamic acid, [5-[[[4-[(diethylamino)carbonyl]-1-piperazinyl]oxy]carbonyl]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 153213-42-4 HCAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, phenyl ester (9CI) (CA INDEX NAME)



=> fil caol;s l3
 COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
58.82	216.13

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-5.54	-5.54

CA SUBSCRIBER PRICE

FILE 'CAOLD' ENTERED AT 09:16:56 ON 01 APR 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

L19 0 L3

=> fil medl,hcapl,biosis,embase,jisct,wpids;s agyin, j?/au,in or agyin j?/au,in;s quada, j?/au,in or quada j?/au,in
 'JISCT' IS NOT A VALID FILE NAME
 Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files

Searched by: Mary Hale 571-272-2507 REM 1D86

that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):jicst

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.68	217.81

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-5.54

FILE 'MEDLINE' ENTERED AT 09:19:10 ON 01 APR 2004

FILE 'HCAPLUS' ENTERED AT 09:19:10 ON 01 APR 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 09:19:10 ON 01 APR 2004

COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 09:19:10 ON 01 APR 2004

COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'JICST-EPLUS' ENTERED AT 09:19:10 ON 01 APR 2004

COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'WPIDS' ENTERED AT 09:19:10 ON 01 APR 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

'IN' IS NOT A VALID FIELD CODE

L20 0 FILE MEDLINE

L21 15 FILE HCAPLUS

L22 11 FILE BIOSIS

'IN' IS NOT A VALID FIELD CODE

L23 2 FILE EMBASE

L24 0 FILE JICST-EPLUS

L25 8 FILE WPIDS

TOTAL FOR ALL FILES

L26 36 AGYIN, J?/AU,IN OR AGYIN J?/AU,IN

'IN' IS NOT A VALID FIELD CODE

L27 5 FILE MEDLINE

L28 19 FILE HCAPLUS

L29 18 FILE BIOSIS

'IN' IS NOT A VALID FIELD CODE

L30 7 FILE EMBASE

L31 0 FILE JICST-EPLUS

L32 6 FILE WPIDS

TOTAL FOR ALL FILES

L33 55 QUADA, J?/AU,IN OR QUADA J?/AU,IN

=> s camden, j?/au,in or camden j?/au,in

'IN' IS NOT A VALID FIELD CODE

L34 38 FILE MEDLINE

L35 93 FILE HCAPLUS

L36 111 FILE BIOSIS

Searched by: Mary Hale 571-272-2507 REM 1D86

'IN' IS NOT A VALID FIELD CODE
L37 27 FILE EMBASE
L38 0 FILE JICST-EPLUS
L39 61 FILE WPIDS

TOTAL FOR ALL FILES
L40 330 CAMDEN, J?/AU, IN OR CAMDEN J?/AU, IN

=> s l26 and l33 and l40
L41 0 FILE MEDLINE
L42 7 FILE HCAPLUS
L43 8 FILE BIOSIS
L44 0 FILE EMBASE
L45 0 FILE JICST-EPLUS
L46 6 FILE WPIDS

TOTAL FOR ALL FILES
L47 21 L26 AND L33 AND L40

=> s l47 not (l13 or l8)
L48 0 FILE MEDLINE
L49 2 FILE HCAPLUS
L50 8 FILE BIOSIS
L51 0 FILE EMBASE
L52 0 FILE JICST-EPLUS

COMBINATION OF STRUCTURE AND TEXT TERMS NOT VALID

The query entered contains both search terms created by structure-building or screen commands and text search terms. L#s created via the STRUCTURE or SCREEN commands must be searched in the structures files separately from text terms or profiles. The L# answer sets from structure searches can be used in crossover searches and can be combined with text terms.

=> fil hcaplu,biosis;s l49

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	11.76	229.57

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-5.54

FILE 'HCAPLUS' ENTERED AT 09:20:11 ON 01 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 09:20:11 ON 01 APR 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

L53 2 FILE HCAPLUS
L54 8 FILE BIOSIS

TOTAL FOR ALL FILES
L55 10 L49

=> dup rme l55
ENTER REMOVE, IDENTIFY, ONLY, OR (?):end

=> dup rem l55
PROCESSING COMPLETED FOR L55

Searched by: Mary Hale 571-272-2507 REM 1D86

L56 10 DUP REM L55 (0 DUPLICATES REMOVED)

=> d cbib abs 1-10

L56 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN

2004:240413 Compounds and methods for use thereof in the treatment of cancer. **Camden, James Berger**; Agyin, Joseph K.; Quada, James C., Jr. (UAF Technologies and Research, LLC, USA). U.S. US 6710065 B1 20040323, 19 pp., Cont.-in-part of U.S. 6,506,783. (English). CODEN: USXXAM. APPLICATION: US 2000-676031 20000929. PRIORITY: US 1997-857811 19970516.

AB Benzimidazole derivs. and salts and prodrugs thereof are disclosed, together with methods for the treatment of cancers or viral infections in warm blooded animals by administration of these compds. Such compds. may be used in combination with a chemotherapeutic agent and/or a potentiator.

L56 ANSWER 2 OF 10 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN

2003:435114 Document No.: PREV200300435114. Compounds and methods for use thereof in the treatment of cancer or viral infections. **Camden, James Berger** [Inventor, Reprint Author]; **Quada, James C. Jr.** [Inventor]; **Agyin, Joseph K.** [Inventor]. ASSIGNEE: University of Arizona Foundation. Patent Info.: US 6608096 August 19, 2003. Official Gazette of the United States Patent and Trademark Office Patents, (Aug 19 2003) Vol. 1273, No. 3. <http://www.uspto.gov/web/menu/patdata.html>. e-file.

ISSN: 0098-1133 (ISSN print). Language: English.

AB Benzimidazole derivatives and salts and prodrugs thereof are disclosed, together with methods for the treatment of cancers or viral infections in warm-blooded animals by administration of these compounds. Such compounds may be used in combination with a chemotherapeutic agent and/or a potentiator.

L56 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN

2002:256239 Document No. 136:289365 Benzimidazole compounds and methods for use thereof in the treatment of cancer or viral infections. **Quada, James C., Jr.**; Agyin, Joseph K.; Camden, James Berger (Procter & Gamble Company, USA). PCT Int. Appl. WO 2002026716 A2 20020404, 42 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US29261 20010919. PRIORITY: US 2000-670169 20000926; US 2000-670168 20000926; US 2000-670170 20000926; US 2000-670166 20000926.

AB Benzimidazole derivs. and salts and prodrugs thereof are disclosed, together with methods for the treatment of cancers or viral infections in warm blooded animals by administration of these compds. Such compds. may be used in combination with a chemotherapeutic agent and/or a potentiator. 2-Aminobenzimidazole was reacted with benzyl isocyanate to give a product that inhibited murine melanoma and human colon carcinoma with IC50s of 73.5 and 66.0 μ M, resp.

L56 ANSWER 4 OF 10 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN

2003:43719 Document No.: PREV200300043719. Compounds and methods for use thereof in the treatment of cancer or viral infections. **Quada, James C. Jr.** [Inventor, Reprint Author]; **Agyin, Joseph K.** [Inventor]; **Camden, James Berger** [Inventor]. ASSIGNEE: The Procter & Gamble Company. Patent Info.: US 6482843 November 19, 2002. Official Gazette of the United States Patent and Trademark Office Patents,

(Nov 19 2002) Vol. 1264, No. 3. <http://www.uspto.gov/web/menu/patdata.html>. e-file.

ISSN: 0098-1133 (ISSN print). Language: English.

AB Benzimidazole derivatives and salts and prodrugs thereof are disclosed, together with methods for the treatment of cancers or viral infections in warm blooded animals by administration of these compounds. Such compounds may be used in combination with a chemotherapeutic agent and/or a potentiator.

L56 ANSWER 5 OF 10 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN 2002:476593 Document No.: PREV200200476593. Compounds and methods for use thereof in the treatment of cancer or viral infections. **Camden, James Berger** [Inventor]; **Agyin, Joseph K.** [Inventor]; **Quada, James C., Jr.** [Inventor]. ASSIGNEE: The Procter and Gamble Company. Patent Info.: US 6423736 July 23, 2002. Official Gazette of the United States Patent and Trademark Office Patents, (July 23, 2002) Vol. 1260, No. 4. <http://www.uspto.gov/web/menu/patdata.html>. e-file.

CODEN: OGUPE7. ISSN: 0098-1133. Language: English.

AB Benzimidazole derivatives and salts and prodrugs thereof are disclosed, together with methods for the treatment of cancers or viral infections in warm blooded animals by administration of these compounds. Such compounds may be used in combination with a chemotherapeutic agent and/or a potentiator.

L56 ANSWER 6 OF 10 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN 2002:476592 Document No.: PREV200200476592. Compounds and methods for use thereof in the treatment of cancer or viral infections. **Camden, James Berger** [Inventor]; **Quada, James C., Jr.** [Inventor]; **Agyin, Joseph K.** [Inventor]. ASSIGNEE: The Procter and Gamble Company. Patent Info.: US 6423735 July 23, 2002. Official Gazette of the United States Patent and Trademark Office Patents, (July 23, 2002) Vol. 1260, No. 4. <http://www.uspto.gov/web/menu/patdata.html>. e-file.

CODEN: OGUPE7. ISSN: 0098-1133. Language: English.

AB Benzimidazole derivatives and salts and prodrugs thereof are disclosed, together with methods for the treatment of cancers or viral infections in warm blooded animals by administration of these compounds. Such compounds may be used in combination with a chemotherapeutic agent and/or a potentiator.

L56 ANSWER 7 OF 10 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN 2002:475376 Document No.: PREV200200475376. Compounds and methods for use thereof in the treatment of cancer or viral infections. **Camden, James Berger** [Inventor]; **Agyin, Joseph K.** [Inventor]; **Quada, James C., Jr.** [Inventor]. ASSIGNEE: The Procter and Gamble Company. Patent Info.: US 6420411 July 16, 2002. Official Gazette of the United States Patent and Trademark Office Patents, (July 16, 2002) Vol. 1260, No. 3. <http://www.uspto.gov/web/menu/patdata.html>. e-file.

CODEN: OGUPE7. ISSN: 0098-1133. Language: English.

AB Benzimidazole derivatives and salts and prodrugs thereof are disclosed, together with methods for the treatment of cancers or viral infections in warm blooded animals by administration of these compounds. Such compounds may be used in combination with a chemotherapeutic agent and/or a potentiator.

L56 ANSWER 8 OF 10 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN 2002:412217 Document No.: PREV200200412217. Compounds and method for use thereof in the treatment of cancer or viral infections. **Quada, James C., Jr.** [Inventor]; **Agyin, Joseph K.** [Inventor]; **Camden, James Berger** [Inventor]. ASSIGNEE: The Procter and Gamble Company. Patent Info.: US 6407131 June 18, 2002. Official Gazette of the United States Patent and Trademark Office Patents, (June 18, 2002) Vol. 1259, No. 3. <http://www.uspto.gov/web/menu/patdata.html>. e-file.

CODEN: OGUPE7. ISSN: 0098-1133. Language: English.

AB Benzimidazole derivatives and salts and prodrugs thereof are disclosed, together with methods for the treatment of cancers or viral infections in warm blooded animals by administration of these compounds. Such compounds may be used in combination with a chemotherapeutic agent and/or a potentiator.

L56 ANSWER 9 OF 10 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN 2002:412194 Document No.: PREV200200412194. Compounds and methods for use thereof in the treatment of cancer or viral infections. **Quada, James C., Jr.** [Inventor]; **Agyin, Joseph K.** [Inventor]; **Camden, James Berger** [Inventor]. ASSIGNEE: The Procter and Gamble Company. Patent Info.: US 6407105 June 18, 2002. Official Gazette of the United States Patent and Trademark Office Patents, (June 18, 2002) Vol. 1259, No. 3. <http://www.uspto.gov/web/menu/patdata.html>. e-file. CODEN: OGUPE7. ISSN: 0098-1133. Language: English.

AB Benzimidazole derivatives and salts and prodrugs thereof are disclosed, together with methods for the treatment of cancers or viral infections in warm blooded animals by administration of these compounds. Such compounds may be used in combination with a chemotherapeutic agent and/or a potentiator.

L56 ANSWER 10 OF 10 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN 2002:315029 Document No.: PREV200200315029. Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof. **Quada, James C., Jr.** [Inventor, Reprint author]; **Agyin, Joseph K.** [Inventor]; **Camden, James Berger** [Inventor]. San Antonio, TX, USA. ASSIGNEE: The Procter and Gamble Company. Patent Info.: US 6380232 April 30, 2002. Official Gazette of the United States Patent and Trademark Office Patents, (Apr. 30, 2002) Vol. 1257, No. 5. <http://www.uspto.gov/web/menu/patdata.html>. e-file. CODEN: OGUPE7. ISSN: 0098-1133. Language: English.

AB Benzimidazole derivatives and salts and prodrugs thereof are disclosed, together with methods for the treatment of cancers or viral infections in warm blooded animals by administration of these compounds. Such compounds may be used in combination with a chemotherapeutic agent and/or a potentiator.

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
27.75	257.32

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-1.39	-6.93

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 09:20:34 ON 01 APR 2004